Titan Pharmaceuticals - Stock Price History | TTNP

Historical daily share price chart and data for Titan Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Titan Pharmaceuticals as of October 26, 2021 is 1.88.
  • The all-time high Titan Pharmaceuticals stock closing price was 1334.87 on May 24, 2016.
  • The Titan Pharmaceuticals 52-week high stock price is 8.86, which is 371.3% above the current share price.
  • The Titan Pharmaceuticals 52-week low stock price is 1.57, which is 16.5% below the current share price.
  • The average Titan Pharmaceuticals stock price for the last 52 weeks is 2.78.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Titan Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 7.0174 6.4565 12.6126 2.9730 3.2900 -43.56%
2019 30.4581 41.4332 60.0601 4.4444 5.8288 -85.49%
2018 141.7532 252.2018 261.2090 34.6777 40.1721 -83.17%
2017 446.6032 837.6703 837.6703 216.1730 238.6910 -66.87%
2016 889.2616 763.8112 1334.8682 536.8296 720.5766 -9.91%
2015 815.1526 826.8617 952.9626 740.3925 799.8400 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.019B $0.005B
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86